false 0001173313 0001173313 2026-08-03 2026-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2026 ABVC BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Nevada 001-40700 26-0014658 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 44370 Old Warm Springs Blvd. Fremont , CA 94538 (Address of principal executive offices) (Zip Code) Registrant’s telephone number including area
code: ( 510 ) 668-0881 (Former name or former address, if changed since
last report) Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Market LLC Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events. On August 3, 2026, ABVC BioPharma, Inc. (the “ Company ”)
determined to postpone the previously announced distribution of ordinary shares of BioKey (Cayman), Inc. (the “ Distribution ”),
which had been scheduled to occur on August 3, 2026. The postponement will provide the Company with additional time to complete certain
administrative, regulatory and tax-related matters necessary to effect the Distribution. The Company is coordinating with The Nasdaq Stock
Market LLC, The Depository Trust Company and the Company’s transfer agent regarding the revised distribution mechanics and the establishment
of updated dates for the Distribution. The previously announced record date remains unchanged,
and the distribution ratio will remain 0.169464 ordinary shares of BioKey (Cayman), Inc. for each share of the Company’s common
stock held as of the record date. The previously announced ex-dividend date will no longer apply and will be revised in connection with
the establishment of a new distribution date. The Company intends to announce the revised distribution
date and corresponding ex-dividend date after such dates have been finalized and the remaining administrative, regulatory, and tax-related
matters have been completed. 1 SIGNATURE Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. August 3, 2026 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2

ABVC Biopharma postponed the distribution of BioKey (Cayman), Inc. ordinary shares originally scheduled for August 3, 2026, to allow time for finalizing administrative, regulatory, and tax-related requirements. The delay impacts shareholders who were expecting to receive 0.169464 BioKey shares per ABVC share held.

On August 3, 2026, ABVC BioPharma, Inc. postponed the distribution of ordinary shares of BioKey (Cayman), Inc., which was originally set for the same date. This decision was made to allow the company additional time to finalize administrative, regulatory, and tax-related requirements involved in the distribution process. The record date for this distribution remains unchanged, and shareholders will receive 0.169464 shares of BioKey for each share of ABVC’s common stock held as of that date. The company is working closely with The Nasdaq Stock Market LLC and The Depository Trust Company for updated distribution mechanics and timelines, indicating significant operational adjustments due to the postponement.

ABVC Biopharma, Inc.

AI Executive Summary

Key Takeaways

Raw Filing Content

Filing Overview

What This Means